Korea Atomic Energy Research Institute

Korea Research Institute of Chemical Technology

Moghu Research Center Ltd

So-Young Lee

Jin Joo Kim

Jae Wook Ryu

Jae Deok Lim

Young Kwan Ko

Dong Wan Koo

Young-Don Hong

Sang Mu Choi

Sun Ju Choi

Dong Eun Lee

Gyu Hwan Yon

Ul Jae Park

Ki-Hwan Hwang

Sun-Ju Choi

Suk-Jin Koo

Jae Cheong Lim

Eun Ha Cho

Sung Soo Nam

Hyun Suk Yeom

Kang-Hyuk Choi

Eun Ae Kim

Dong-Guk Lee

Jun-Ho Nam

Mi-Young Kwak

Nam-Gyu Cho

Kun-Hoe Chung

Jong-Su Lim

Sung-Hun Kim

Hee Nam Lim

Chan Yong Park

Provided is a novel compound capable of being usefully used to diagnose and treat prostate cancer by labeling a radioisotope on a bombesin derivatives capable of selectively targeting a target material over-expressed in tumor cells in order to develop an effective diagnose and treatment method of diseases associated with prostate cancer.

GRP-R agonistic 177-lutetium-labeled bombesin derivatives for diagnosis and treatment of prostate cancer

Novel NSchelator-folate derivatives, a preparation method thereof, and a composition for diagnosis and treatment of tumor including the same as an active ingredient are provided. The novel NSchelator-folate derivatives or a pharmaceutically acceptable salt thereof are easily introduced into the cells using receptor binding to tumor expressing &#x3b1;-folate receptor (&#x3b1;-FR). Accordingly, the folate derivatives, labeled with radioisotope such as technetium, or rhenium, can be advantageously used for the diagnosis and treatment of tumor using tumor imaging and irradiation from the isotope, and therefore, can be widely used for the purpose of labeling a variety of radiopharmaceuticals.

[object Object]

Disclosed are chelating agent-conjugated &#x3b1;-MSH peptide derivatives, preparation methods thereof, and compositions for use in a diagnosis or treatment of a melanoma tumor containing the same as an active ingredient. The novel &#x3b1;-MSH peptide derivatives conjugated with chelating agent according to the present invention are highly selective to the melanocortin-1 receptor which is &#x3b1;-MSH receptor expressing in melanoma tumor and their labeling rate of a radioactive isotope is high. Also, they remain in kidney shortly and have high taking rate of the melanoma tumor. Therefore, with the aforesaid reasons, they may be effectively used for early diagnosis or treatment of melanoma tumor.

Chelating agent conjugated &#x3b1;-MSH peptide derivatives, preparation method thereof and composition for diagnosis and treatment of melanoma comprising the same as an active ingredient

Growing community of inventors

Daejeon, South Korea

So-Young Lee